AVEO Pharmaceuticals (AVEO) stock price, revenue, and financials

AVEO Pharmaceuticals market cap is $219.9 m, and annual revenue was $6.02 m in FY 2020

$219.9 M

AVEO Mkt cap, 14-Sept-2021

$1.9 M

AVEO Pharmaceuticals Revenue Q1, 2021
AVEO Pharmaceuticals Net income (Q1, 2021)-22.1 M
AVEO Pharmaceuticals EBIT (Q1, 2021)-19.1 M
AVEO Pharmaceuticals Cash, 31-Mar-2021121.4 M
AVEO Pharmaceuticals EV155.5 M
Get notified regarding key financial metrics and revenue changes at AVEO PharmaceuticalsLearn more
Banner background

AVEO Pharmaceuticals Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

26.6m3.6m860.0k1.9m1.0m323.0k324.0k323.0k15.3m1.8m873.0k134.0k134.0k15.2m1.2m193.0k992.0k2.5m351.0k4.6m1.0m433.0k2.5m1.6m703.0k25.7m784.0k749.0k1.9m

R&D expense

25.1m20.1m24.8m21.5m21.1m21.0m16.2m19.4m11.8m9.3m8.5m2.7m1.8m4.5m6.0m5.6m4.4m8.0m6.9m4.7m5.4m4.9m5.2m6.9m2.6m4.0m7.8m4.4m5.8m

General and administrative expense

6.4m6.6m9.0m9.2m9.3m12.4m7.3m4.4m5.6m4.8m5.1m3.3m2.9m2.2m2.5m1.7m2.1m2.3m2.3m2.1m2.6m2.8m2.7m2.5m3.0m2.9m3.7m3.7m15.1m

Operating expense total

31.4m26.7m33.8m30.6m30.4m33.4m23.5m23.9m17.3m14.1m13.6m6.0m4.7m6.7m8.4m7.3m6.6m10.3m9.2m6.8m8.0m7.7m7.9m9.3m5.6m6.9m11.5m8.2m20.9m

Depreciation and amortization

5.0k

EBIT

(4.9m)(23.1m)(32.9m)(28.8m)(29.4m)(33.2m)(31.1m)(23.6m)(5.9m)(17.5m)(14.1m)(10.1m)(4.6m)8.5m(7.2m)(7.1m)(5.6m)(7.8m)(8.8m)(2.2m)(7.0m)(6.6m)(5.4m)(7.7m)(4.9m)18.9m(10.7m)(7.4m)(19.1m)

EBIT margin, %

(18%)(644%)(3825%)(1532%)(2886%)(10265%)(9590%)(7309%)(39%)(946%)(1615%)(7574%)(3449%)56%(601%)(3701%)(564%)(306%)(2516%)(47%)(685%)(1518%)(219%)(478%)(696%)73%(1367%)(989%)(996%)

Interest expense

946.0k953.0k845.0k880.0k888.0k870.0k825.0k611.0k

Interest income

99.0k168.0k199.0k159.0k101.0k41.0k35.0k26.0k16.0k10.0k4.0k5.0k7.0k2.0k17.0k

Pre tax profit

(7.6m)(8.6m)(5.0m)(8.8m)(33.3m)(26.3m)(9.0m)4.0m(22.2m)

Income tax expense

100.0k50.0k51.0k

Net Income

(5.7m)(23.8m)(33.2m)(29.5m)(30.1m)(34.1m)(31.9m)(24.3m)(6.4m)(18.0m)(14.4m)(10.9m)(5.5m)7.9m(7.7m)(8.6m)(5.0m)(8.8m)(33.3m)(26.4m)(9.0m)4.0m(22.2m)555.0k(3.1m)16.4m(8.4m)(7.3m)(22.1m)

AVEO Pharmaceuticals Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

81.0m45.9m73.1m85.8m114.1m85.9m33.8m50.4m46.3m43.4m60.0m34.5m26.8m34.7m18.1m25.3m12.4m33.4m30.9m16.4m16.2m18.1m20.4m23.5m40.2m57.7m23.5m45.7m121.4m

Accounts Receivable

28.8m9.7m9.5m9.2m9.3m9.2m7.9m8.9m1.3m1.2m1.7m947.0k2.3m2.3m1.7m1.3m990.0k676.0k445.0k2.4m600.0k973.0k344.0k2.6m611.0k1.1m2.8m1.2m1.1m

Prepaid Expenses

9.3m5.6m3.5m5.2m7.8m9.7m9.2m7.2m2.0m3.7m3.3m1.4m1.4m1.4m1.1m

Current Assets

302.4m275.1m237.3m230.3m206.8m210.6m173.3m146.5m105.6m85.4m71.5m44.4m33.4m43.8m30.7m42.3m34.0m35.9m42.1m41.5m43.6m20.0m21.4m26.3m41.7m59.8m37.1m74.2m126.1m

PP&E

5.0m5.2m6.0m6.6m7.9m13.3m13.2m12.8m19.0m15.9m14.7m5.4m131.0k52.0k18.0k22.0k23.0k100.0k96.0k326.0k

Total Assets

340.8m317.8m264.7m240.9m218.5m227.8m190.4m163.1m127.8m104.2m86.2m50.0m33.7m44.0m30.8m42.7m35.1m36.6m42.5m41.7m43.6m20.0m21.4m26.5m41.7m59.8m38.5m75.6m127.4m

Accounts Payable

12.9m9.7m7.6m4.3m10.3m8.1m7.2m6.1m4.0m3.5m1.7m2.6m1.6m290.0k340.0k2.1m1.2m3.3m3.4m1.9m3.4m2.8m3.0m2.1m2.0m2.2m3.0m1.8m4.0m

Short-term debt

6.0m6.1m10.1m10.1m13.5m13.5m10.0m10.7m11.1m8.0m9.9m8.0m4.2m3.0m766.0k3.5m3.1m4.9m586.0k2.4m4.3m5.7m8.2m9.3m10.3m10.6m11.8m

Current Liabilities

33.0m31.9m25.0m29.1m34.7m37.7m34.7m31.7m32.6m33.0m38.9m26.6m14.5m10.4m10.9m7.0m6.8m14.2m15.0m17.8m32.4m17.2m19.5m18.9m18.9m20.8m22.0m21.8m19.8m

Long-term debt

17.8m17.9m25.8m26.5m26.5m26.5m24.2m11.5m6.0m3.1m12.5m8.1m7.3m8.3m6.5m13.7m13.1m10.6m16.1m14.3m18.0m16.3m14.6m13.5m11.2m8.7m4.2m1.4m45.2m

Total Debt

23.9m24.0m25.8m36.6m36.6m40.0m37.7m21.6m16.7m14.2m20.4m18.0m15.3m12.5m9.6m13.7m13.9m14.1m19.1m19.2m18.6m18.7m18.9m19.2m19.3m18.0m14.5m12.1m57.0m

Total Liabilities

34.4m31.6m31.7m61.8m86.3m93.9m65.5m81.8m45.1m40.0m41.0m31.5m27.6m55.0m

Common Stock

43.0k43.0k44.0k44.0k44.0k52.0k52.0k52.0k52.0k52.0k52.0k55.0k56.0k58.0k58.0k76.0k76.0k110.0k117.0k118.0k119.0k119.0k121.0k139.0k161.0k161.0k161.0k26.0k34.0k

Preferred Stock

Additional Paid-in Capital

424.7m427.2m431.9m434.4m436.9m495.5m495.1m496.3m497.9m498.6m500.4m505.4m507.5m512.3m512.6m519.6m519.7m535.6m544.6m545.8m548.3m549.1m556.3m575.7m599.1m599.8m600.8m649.3m715.7m

Retained Earnings

(156.9m)(180.7m)(239.1m)(268.7m)(298.8m)(354.3m)(386.3m)(410.6m)(433.7m)(451.7m)(466.1m)(490.9m)(496.4m)(488.4m)(502.7m)(511.3m)(516.3m)(530.8m)(564.1m)(590.5m)(598.7m)(594.7m)(616.8m)(594.5m)(597.6m)(581.2m)(594.0m)(601.3m)(643.3m)

Total Equity

268.0m246.3m192.9m165.8m138.2m141.2m108.9m85.8m64.3m47.0m34.3m14.6m11.2m23.9m9.9m8.3m3.5m4.9m(19.3m)(44.6m)(50.2m)(45.4m)(60.4m)(18.6m)1.6m18.8m7.0m48.1m72.4m

Debt to Equity Ratio

0.2 x0.3 x0.3 x0.3 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x0.2 x

Financial Leverage

1.3 x1.3 x1.4 x1.5 x1.6 x1.6 x1.7 x1.9 x2 x2.2 x2.5 x3.4 x3 x1.8 x3.1 x5.1 x9.9 x7.4 x-2.2 x-0.9 x-0.9 x-0.4 x-0.4 x-1.4 x25.5 x3.2 x5.5 x1.6 x1.8 x

AVEO Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

79.6m55.8m(33.2m)(62.8m)(92.9m)(34.1m)(66.0m)(90.3m)(6.4m)(24.4m)(38.8m)(10.9m)(16.3m)(8.4m)(7.7m)(16.3m)(21.3m)(8.8m)(42.1m)(68.5m)(9.0m)(5.0m)(27.1m)555.0k(2.6m)13.8m(8.4m)(15.7m)(22.1m)

Depreciation and Amortization

765.0k1.2m546.0k1.1m1.8m1.9m2.8m838.0k1.7m2.8m4.5m9.5m9.6m5.0k7.0k7.0k4.0k17.0k

Accounts Receivable

(28.4m)(9.4m)(2.3m)(2.0m)(2.1m)12.8m11.8m(270.0k)(251.0k)(674.0k)1.4m21.0k7.0k2.9m3.3m3.7m351.0k582.0k(1.3m)(198.0k)(571.0k)58.0k455.0k2.4m1.9m(1.1m)423.0k

Accounts Payable

3.7m431.0k(1.3m)(4.6m)1.4m(3.4m)(4.5m)(1.6m)(738.0k)(2.6m)(626.0k)(1.7m)(3.0m)(1.1m)656.0k(246.0k)1.1m1.2m(245.0k)944.0k386.0k547.0k(1.4m)(1.5m)(1.3m)1.5m319.0k583.0k

Cash From Operating Activities

45.5m46.4m(30.6m)(58.3m)(82.4m)(53.5m)(75.7m)(19.8m)(35.2m)(43.2m)(15.8m)(27.2m)(18.2m)(10.3m)(14.9m)(23.6m)(5.4m)(12.4m)(15.4m)(6.5m)(15.6m)(18.4m)(8.5m)(14.5m)4.5m(11.7m)(19.2m)(18.3m)

Purchases of PP&E

(1.2m)(1.8m)(1.1m)(2.3m)(4.2m)(2.0m)(3.0m)(7.8m)(11.8m)(12.9m)(14.0k)(7.0k)(100.0k)(100.0k)

Cash From Investing Activities

(124.2m)(160.9m)58.5m98.2m150.2m(40.6m)645.0k17.8m34.1m51.4m(3.6m)1.2m(1.3m)1.8m(6.7m)(10.9m)8.3m(1.0m)(12.8m)7.7m18.6m18.6m7.7m(7.8m)

Long-term Borrowings

(4.7m)(2.5m)(6.4m)(7.8m)(2.8m)(5.6m)(8.5m)(1.5m)(2.4m)(4.8m)

Cash From Financing Activities

113.9m114.7m1.7m2.3m2.8m51.7m49.4m(2.5m)(6.3m)1.0m1.7m522.0k2.0m(13.0k)20.3m20.3m15.5m29.2m29.5m(7.0k)163.0k5.3m7.5m30.3m28.8m(2.4m)42.9m78.0m

Net Change in Cash

35.2m122.0k29.6m42.3m70.6m(42.3m)(25.7m)(4.5m)(7.5m)9.2m(17.8m)(25.5m)(17.6m)(8.6m)(1.3m)(14.3m)18.3m15.8m1.3m1.2m3.1m5.5m(944.0k)15.8m33.2m(6.3m)15.9m59.7m

Interest Paid

1.5m2.3m731.0k1.5m2.3m1.6m2.3m553.0k1.0m1.4m617.0k1.2m1.6m301.0k631.0k1.1m446.0k902.0k1.5m509.0k992.0k1.5m507.0k1.0m1.5m368.0k681.0k362.0k

AVEO Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

1.3 x

AVEO Pharmaceuticals Employee Rating

3.710 votes
Culture & Values
3.6
Work/Life Balance
3.5
Senior Management
2.7
Salary & Benefits
3.8
Career Opportunities
3.4
Source